On Thursday 16 February, the Conference of Presidents of the European Parliament’s political groups decided not to withdraw or suspend the access of Pfizer’s Chief Executive Officer, Albert Bourla to the European Parliament, nor the access of other representatives of the company (see EUROPE B13098A9).
The coordinators of the special parliamentary committee set up to identify the lessons learned from the Covid-19 pandemic (COVI) had adopted on Wednesday 11 January the request of the...